1. Home
  2. ABUS vs UTI Comparison

ABUS vs UTI Comparison

Compare ABUS & UTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$5.11

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Universal Technical Institute Inc

UTI

Universal Technical Institute Inc

HOLD

Current Price

$22.46

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
UTI
Founded
2005
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2008
2003

Fundamental Metrics

Financial Performance
Metric
ABUS
UTI
Price
$5.11
$22.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$5.00
$37.50
AVG Volume (30 Days)
4.2M
1.8M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
55.26
50.67
EPS
0.84
0.28
Revenue
$14,083,000.00
$835,616,000.00
Revenue This Year
N/A
$10.15
Revenue Next Year
$239.71
$8.32
P/E Ratio
$6.14
$79.29
Revenue Growth
128.21
14.05
52 Week Low
$3.50
$20.33
52 Week High
$5.45
$51.34

Technical Indicators

Market Signals
Indicator
ABUS
UTI
Relative Strength Index (RSI) 61.60 34.26
Support Level $4.99 N/A
Resistance Level $5.42 $26.98
Average True Range (ATR) 0.14 1.30
MACD -0.00 0.58
Stochastic Oscillator 54.23 42.75

Price Performance

Historical Comparison
ABUS
UTI

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About UTI Universal Technical Institute Inc

Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.

Share on Social Networks: